A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei
- 754 Downloads
The efficacy of cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) for patients with pseudomyxoma peritonei (PMP) remains to be established.
Searches for all relevant studies prior to March 2006 were performed on six databases. Two reviewers independently appraised each study using a predetermined protocol. The quality of each study was assessed. Clinical effectiveness was synthesized through a narrative review with full tabulation of results of all included studies.
Ten most recent updates from each institution were included for appraisal and data extraction. There were no randomized controlled trials or comparative studies. All included articles were observational studies without control groups. Five studies were relatively large series (n≥100). Two studies had relatively long-term follow-up (48 months and 52 months). The median follow-up in the remaining eight studies was shorter than 3 years (range 19–35 months). The median survival ranged from 51 to 156 months. The 1-, 2-, 3- and 5-year survival rates varied from 80 to 100%, 76 to 96%, 59 to 96% and 52 to 96%, respectively. The overall morbidity rate varied from 33 to 56%. The overall mortality rates ranged from 0 to 18%.
This study reviewed current evidence on CRS and PIC for PMP. Only observational studies were available for evaluation, which demonstrated some promising long-term results, as compared to historical controls. Due to the rarity of this disease, a well-designed prospective multi-institutional study would be meaningful.
KeywordsPseudomyxoma peritonei Cytoreductive surgery Intraperitoneal chemotherapy Appendiceal neoplasms Systematic review
Tristan D. Yan, a surgical oncology research fellow, is supported by Foundation for Applied Research in Gastrointestinal Oncology and Medstar Research Institute.
- 11.Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to “pseudomyxoma peritonei.” Am J Surg Pathol 1995;19:1390–408PubMedGoogle Scholar
- 12.NHS Centre for Reviews and Dissemination. Undertaking systemic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews. CRD report 4, 2nd ed. York: NHS Centre for Reviews and Dissemination; 2001Google Scholar
- 14.Sugarbaker PH. Curative treatment of peritoneal carcinomatosis from grade I mucinous adenocarcinoma. Surg Rounds 1988; 45–63Google Scholar
- 15.Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis. Cancer J Surg 1989;32:164–70Google Scholar
- 18.Fernandez-Trigo V, Shamsa F, Sugarbaker PH. Clinical determinants of treatment failures after cytoreductive surgery and intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Acta Chr Austriaca 1995;97–183Google Scholar
- 21.Zoetmulder FAN, Sugarbaker PH. Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Eur J Surg Oncol 1996; 32A:1727–33Google Scholar
- 33.van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002;9:961–7PubMedCrossRefGoogle Scholar
- 36.Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FAN. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic chemotherapy. Ann Surg, (in press)Google Scholar